GO:1903403 negative regulation of renal phosphate excretion: Physiology, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1903403 describes any biological process that stops, prevents, or reduces the frequency, rate, or extent of renal phosphate excretion.
• The term is a biological_process node that sits at the intersection of mineral homeostasis, hormone signaling, and renal tubular transport.
• Key molecular players include PTH, FGF23, vitamin D, and the sodium-phosphate cotransporters SLC34A1 and SLC34A3.
• Dysregulation of this process underlies hyperphosphatemia, chronic kidney disease, and vascular calcification.
• Osteocytes and the bone-kidney axis are central to the endocrine control of renal phosphate reabsorption.
• CRISPR knockout, knock-in, and overexpression models are essential for dissecting the causal genes in this pathway.
Description
Phosphate is an essential mineral that participates in skeletal mineralization, energy metabolism, and intracellular signaling. The kidney is the principal organ that determines the final amount of phosphate excreted in urine, and the process of negative regulation of renal phosphate excretion ensures that phosphate is retained when body stores are low or when hormonal signals demand conservation. This Gene Ontology term, GO:1903403, captures the regulatory logic that reduces phosphate loss through the kidney, integrating hormonal, paracrine, and tubular transport mechanisms. Understanding this process is critical because disorders of phosphate homeostasis cause rickets, osteomalacia, nephrocalcinosis, and cardiovascular calcification. Researchers studying GO:1903403 need a precise definition, a map of the genes involved, and experimental strategies to test causality.
negative regulation of renal phosphate excretion At A Glance
| GO ID | GO:1903403 |
|---|---|
| GO term | negative regulation of renal phosphate excretion |
| Ontology | biological_process |
| Synonym | down regulation of renal phosphate excretion; inhibition of renal phosphate excretion; negative regulation of renal phosphate ion excretion |
| Major function | Reduces the frequency, rate, or extent of phosphate excretion by the kidney |
| Key regulators | PTH, FGF23, vitamin D, SLC34A1, SLC34A3 |
| Cellular location | Renal proximal tubule brush border membrane |
| Related processes | Phosphate homeostasis, bone mineralization, vitamin D metabolism |
What Is GO:1903403?
GO:1903403, negative regulation of renal phosphate excretion, is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of renal phosphate excretion. In practical terms, it encompasses the hormonal and cellular events that decrease the amount of phosphate eliminated by the kidney, thereby increasing or maintaining plasma phosphate concentrations. This regulation occurs primarily in the proximal tubule, where sodium-dependent phosphate cotransporters mediate reabsorption, and it is modulated by parathyroid hormone (PTH), fibroblast growth factor 23 (FGF23), and vitamin D.
Why Is negative regulation of renal phosphate excretion Important in Cell Biology?
Negative regulation of renal phosphate excretion is a central node in mineral homeostasis because it determines how much phosphate is retained by the body. When this process is excessive, hyperphosphatemia can drive vascular calcification and cardiovascular disease. When it is insufficient, renal phosphate wasting leads to hypophosphatemic rickets and osteomalacia. The process is also a target of therapeutic strategies in chronic kidney disease, where reducing phosphate retention is a clinical goal. Therefore, understanding GO:1903403 is essential for both basic physiology and translational medicine.
• Maintains plasma phosphate within a narrow physiological range.
• Integrates hormonal signals from PTH, FGF23, and vitamin D.
• Controls skeletal mineralization and bone quality.
• Dysregulation causes hyperphosphatemia and vascular calcification.
• Loss of function leads to hypophosphatemic rickets.
• Provides a mechanistic basis for CKD-mineral and bone disorder.
• Serves as a model for studying epithelial transport regulation.
• Involves the calcium-sensing receptor in modulating phosphate handling.
• Is a target for drugs that lower phosphate in kidney disease.
• Requires precise CRISPR models to establish causality of candidate genes.
What Happens During negative regulation of renal phosphate excretion?
Hormonal sensing of phosphate status
In simple terms: The body first detects whether phosphate levels are too high or too low.
Negative regulation of renal phosphate excretion begins with endocrine and paracrine signals that report phosphate status. PTH is released in response to low calcium or high phosphate and acts on the proximal tubule to reduce phosphate reabsorption, but under conditions where phosphate conservation is needed, FGF23 and vitamin D act to modulate this response. FGF23, produced by osteocytes, is a key hormone that reduces renal phosphate reabsorption and suppresses vitamin D activation. The calcium-sensing receptor also contributes to the regulation of renal phosphate handling by sensing extracellular calcium.
Proximal tubule transport machinery
In simple terms: Specialized transporter proteins in the kidney tubule decide how much phosphate is pulled back into the blood.
The proximal tubule expresses sodium-dependent phosphate cotransporters, primarily SLC34A1 (NaPi-IIa) and SLC34A3 (NaPi-IIc), which mediate phosphate reabsorption from the filtrate. Negative regulation of renal phosphate excretion involves increasing the activity or abundance of these transporters at the brush border membrane, thereby reducing phosphate loss in urine. This process is tightly linked to the endocytic retrieval and recycling of cotransporters, which is controlled by hormonal signals.
Intracellular signaling and transporter trafficking
In simple terms: Signals inside the tubule cell tell the transporters to stay on the surface or be removed.
PTH and FGF23 activate intracellular signaling cascades that lead to phosphorylation of the cotransporter and its internalization, which would increase phosphate excretion. Conversely, negative regulation of renal phosphate excretion can occur when these signals are suppressed or when other pathways promote the stabilization of SLC34A1 and SLC34A3 at the membrane. The balance between insertion and retrieval of these transporters determines the net reabsorptive capacity of the kidney.
Integration with calcium and water handling
In simple terms: Phosphate regulation does not happen in isolation; it is coordinated with calcium and fluid balance.
The calcium-sensing receptor modulates renal calcium, phosphate, electrolyte, and water excretion, providing a mechanism for cross-talk between calcium and phosphate homeostasis. This integration ensures that negative regulation of renal phosphate excretion is adjusted according to systemic calcium needs and extracellular fluid volume. Acid-base status also influences phosphate handling, as combined deletion of NBCe1-A and NBCe1-B affects renal phosphate excretion in mouse models.
Bone-kidney axis and osteocyte signaling
In simple terms: Bone cells act as sensors that tell the kidney to hold onto phosphate.
Osteocytes are the major source of FGF23, which acts on the kidney to reduce phosphate reabsorption and is a central component of the bone-kidney axis. In conditions where phosphate conservation is required, FGF23 levels may be suppressed, allowing increased expression of sodium-phosphate cotransporters and thus negative regulation of renal phosphate excretion. This axis is critical for maintaining phosphate balance during growth, aging, and disease.
Key Genes Involved in GO:1903403 negative regulation of renal phosphate excretion
The following genes and proteins are central to the regulation of renal phosphate excretion and are frequently studied in the context of GO:1903403.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FGF23 | Hormone that reduces renal phosphate reabsorption | Key regulator of phosphate homeostasis; mutations cause hypophosphatemic rickets |
| PTH | Hormone that inhibits phosphate reabsorption in proximal tubule | Central to calcium-phosphate balance; used to study hormonal control |
| SLC34A1 | Sodium-phosphate cotransporter NaPi-IIa | Mediates phosphate reabsorption; target of PTH and FGF23 |
| SLC34A3 | Sodium-phosphate cotransporter NaPi-IIc | Mutations cause hereditary hypophosphatemic rickets with hypercalciuria |
| VDR | Vitamin D receptor | Mediates vitamin D effects on phosphate and calcium homeostasis |
| CYP27B1 | 1-alpha-hydroxylase | Activates vitamin D; regulated by FGF23 and PTH |
| CYP24A1 | 24-hydroxylase | Inactivates vitamin D; feedback regulator |
| CASR | Calcium-sensing receptor | Modulates renal calcium and phosphate excretion |
| SLC9A3R1 | Scaffolding protein NHERF1 | Regulates cotransporter trafficking and PTH signaling |
| SLC34A2 | Sodium-phosphate cotransporter NaPi-IIb | Expressed in other tissues; may compensate in kidney |
| KL | Klotho | Co-receptor for FGF23; essential for FGF23 signaling |
| FGFR1 | FGF receptor 1 | Mediates FGF23 signaling in kidney |
| NBCe1-A | Sodium-bicarbonate cotransporter | Acid-base effects on phosphate excretion |
| NBCe1-B | Sodium-bicarbonate cotransporter | Acid-base effects on phosphate excretion |
| Osteocyte markers (DMP1, PHEX) | Regulate FGF23 production | Bone-kidney axis; mutations cause phosphate wasting |
| SLC20A1 | Type III sodium-phosphate cotransporter | May contribute to phosphate transport in kidney |
| SLC20A2 | Type III sodium-phosphate cotransporter | May contribute to phosphate transport in kidney |
How Is negative regulation of renal phosphate excretion Regulated?
The process of negative regulation of renal phosphate excretion is itself regulated by a network of hormonal and metabolic signals. PTH and FGF23 are the primary hormones that reduce phosphate reabsorption, while vitamin D and its metabolites can increase phosphate reabsorption depending on context. The calcium-sensing receptor modulates these effects by sensing extracellular calcium. Acid-base disturbances also influence phosphate handling, as demonstrated by combined deletion of NBCe1-A and NBCe1-B in mice. Additionally, osteocytes regulate FGF23 production in response to phosphate and vitamin D, forming a feedback loop that adjusts renal phosphate excretion.
negative regulation of renal phosphate excretion and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FGF23 | Hypophosphatemic rickets, CKD-MBD | Knockout and knock-in mouse models; overexpression |
| SLC34A3 | Hereditary hypophosphatemic rickets with hypercalciuria | Knockout and point-mutation models |
| SLC34A1 | Nephrolithiasis, osteoporosis | Knockout and overexpression models |
| CASR | Familial hypocalciuric hypercalcemia | Point-mutation knock-in models |
| NBCe1-A/B | Acid-base and phosphate handling defects | Double knockout models |
Hyperphosphatemia and vascular calcification
When negative regulation of renal phosphate excretion is excessive or when kidney function declines, phosphate retention leads to hyperphosphatemia. Elevated phosphate promotes vascular smooth muscle cell calcification, and recent evidence suggests that vascular calcification maladaptively participates in acute phosphate homeostasis. This creates a vicious cycle that contributes to cardiovascular morbidity in chronic kidney disease.
Hypophosphatemic rickets and osteomalacia
Insufficient negative regulation of renal phosphate excretion, often due to mutations in SLC34A3 or dysregulated FGF23, causes renal phosphate wasting and hypophosphatemic rickets. Genetic disorders of renal phosphate handling are a major cause of inherited rickets and osteomalacia. These conditions highlight the importance of precise regulation of phosphate reabsorption for skeletal health.
Chronic kidney disease and mineral bone disorder
In chronic kidney disease, impaired phosphate excretion leads to compensatory increases in FGF23 and PTH, which attempt to maintain phosphate balance but eventually fail. This contributes to CKD-mineral and bone disorder, characterized by vascular calcification, bone abnormalities, and fractures. Targeting the pathways that regulate renal phosphate excretion is a therapeutic strategy in this population.
From negative regulation of renal phosphate excretion-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of FGF23 increase renal phosphate reabsorption? | FGF23 knockout mouse |
| Does a specific SLC34A3 mutation cause transporter mislocalization? | Point-mutation knock-in |
| Can overexpression of SLC34A1 reduce phosphate excretion? | Transgenic overexpression |
| How does CASR modulate phosphate handling? | CASR knockout or point-mutation knock-in |
| What is the role of NBCe1-A in phosphate excretion? | NBCe1-A knockout |
| Does vascular calcification affect acute phosphate homeostasis? | Vascular calcification mouse models |
How to Study the negative regulation of renal phosphate excretion Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss of gene function | Test necessity of candidate genes |
| CRISPR knock-in | Specific mutation effects | Model patient variants |
| Metabolic cage | Urinary phosphate excretion | Assess renal phosphate handling in vivo |
| Western blot | Protein abundance | Measure cotransporter levels |
| Immunofluorescence | Protein localization | Assess brush border localization |
| RNA-seq | Transcriptome changes | Identify regulated pathways |
| Hormone assays | PTH, FGF23, vitamin D levels | Systemic context |
Genetic knockout and knock-in models
CRISPR-Cas9 mediated knockout of candidate genes such as FGF23, SLC34A1, or SLC34A3 allows researchers to test their necessity in negative regulation of renal phosphate excretion. Knock-in of patient-specific mutations can reveal the functional impact of variants found in hypophosphatemic rickets. These models are essential for establishing causality in the bone-kidney axis.
Biochemical and transport assays
Phosphate transport assays in isolated brush border membrane vesicles or cultured proximal tubule cells measure the direct effect of genetic manipulation on reabsorption capacity. Western blotting and immunofluorescence can assess the abundance and localization of sodium-phosphate cotransporters. Hormone measurements (PTH, FGF23, vitamin D) provide systemic context.
In vivo phosphate balance studies
Metabolic cage studies in mice can quantify urinary phosphate excretion and calculate fractional excretion, directly reflecting the activity of GO:1903403. These studies are often combined with dietary phosphate manipulation to challenge the regulatory system. Such experiments are critical for translating molecular findings to whole-animal physiology.
Omics and bioinformatics
RNA-seq and proteomics of kidney cortex or proximal tubule cells can identify global changes in gene expression following genetic or hormonal perturbations. Bioinformatics analysis of transcriptomic data can reveal co-regulated networks involving FGF23, PTH, and vitamin D signaling. These approaches help generate hypotheses about novel regulators of renal phosphate excretion.
How CRISPR Can Be Used to Study GO:1903403 negative regulation of renal phosphate excretion
Knockout
CRISPR knockout of genes such as FGF23 or SLC34A3 in cell lines or mice can determine whether they are required for negative regulation of renal phosphate excretion. For example, knockout of NBCe1-A and NBCe1-B in mice altered renal phosphate excretion, demonstrating the utility of this approach. Knockout models are the gold standard for loss-of-function studies in this pathway.
Point Mutation
Point mutations identified in patients with hypophosphatemic rickets can be introduced into the endogenous locus using CRISPR base editing or homology-directed repair. These models allow precise testing of whether a specific amino acid change impairs transporter function or trafficking. Such studies are essential for variant classification and mechanistic understanding.
Knock-in
Knock-in of reporter tags or humanized sequences can facilitate tracking of cotransporter localization and dynamics in vivo. For example, tagging SLC34A1 with a fluorescent protein enables live imaging of its membrane trafficking in response to PTH. Knock-in models are also used to humanize the FGF23 locus for drug testing.
Overexpression
Overexpression of SLC34A1 or SLC34A3 in transgenic models can test whether increased cotransporter abundance enhances negative regulation of renal phosphate excretion. Conversely, overexpression of FGF23 can drive phosphate wasting and hypophosphatemia. These models complement knockout studies by providing gain-of-function evidence.
How EDITGENE Supports negative regulation of renal phosphate excretion Research
Researchers studying negative regulation of renal phosphate excretion-related genes often need to determine whether a candidate gene is causally involved in phosphate handling or simply correlated with it. This requires precise genetic models that can isolate the contribution of individual genes and variants. EDITGENE provides a comprehensive suite of CRISPR services to accelerate this discovery process.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of renal phosphate excretion research.
Frequently Asked Questions About negative regulation of renal phosphate excretion
What is GO:1903403?
GO:1903403 is the Gene Ontology term for negative regulation of renal phosphate excretion, defined as any process that stops, prevents, or reduces the frequency, rate, or extent of phosphate excretion by the kidney.
What genes are involved in negative regulation of renal phosphate excretion?
Key genes include FGF23, PTH, SLC34A1, SLC34A3, VDR, CYP27B1, CYP24A1, CASR, and KL, among others.
How does FGF23 reduce renal phosphate excretion?
FGF23 acts on the kidney to reduce phosphate reabsorption by downregulating sodium-phosphate cotransporters, thereby increasing phosphate excretion; its suppression allows negative regulation of phosphate excretion.
What diseases are associated with defects in renal phosphate excretion?
Hyperphosphatemia, vascular calcification, hypophosphatemic rickets, osteomalacia, and chronic kidney disease-mineral and bone disorder.
What is the role of the calcium-sensing receptor in phosphate handling?
The calcium-sensing receptor modulates renal calcium, phosphate, electrolyte, and water excretion, providing cross-talk between calcium and phosphate homeostasis.
How can I study negative regulation of renal phosphate excretion in the lab?
Use CRISPR knockout or knock-in models, metabolic cage studies, transport assays, and omics approaches to dissect the pathway.
What cell models are available for phosphate transport research?
Proximal tubule cell lines, HEK293 cells overexpressing SLC34A1, and primary osteocytes for FGF23 studies are commonly used.
What is the bone-kidney axis in phosphate homeostasis?
The bone-kidney axis refers to the endocrine communication where osteocytes produce FGF23, which acts on the kidney to regulate phosphate reabsorption.
How does acid-base status affect renal phosphate excretion?
Acid-base disturbances can alter phosphate handling; combined deletion of NBCe1-A and NBCe1-B in mice affects renal phosphate excretion.
Can CRISPR be used to model hypophosphatemic rickets?
Yes, CRISPR knock-in of patient mutations in SLC34A3 or FGF23 can model hypophosphatemic rickets and test variant pathogenicity.
Conclusion
GO:1903403, negative regulation of renal phosphate excretion, is a critical biological process that maintains phosphate balance through the coordinated actions of hormones, transporters, and bone-derived signals. Its dysregulation leads to significant human diseases, including rickets, hyperphosphatemia, and vascular calcification. Advances in CRISPR genome editing now allow precise dissection of the genes and variants that control this process, offering new opportunities for therapeutic development. Researchers can leverage EDITGENE's services to build the models needed to move this field forward.
References
- 1. Peacock M. 2010. Calcium metabolism in health and disease.. Clin J Am Soc Nephrol 5 Suppl 1:S23-30 PMID: 20089499
- 2. Tyler Miller R. 2013. Control of renal calcium, phosphate, electrolyte, and water excretion by the calcium-sensing receptor.. Best Pract Res Clin Endocrinol Metab 27(3):345-58 PMID: 23856264
- 3. Michigami T. 2022. Roles of osteocytes in phosphate metabolism.. Front Endocrinol (Lausanne) 13:967774 PMID: 35909535
- 4. Bergwitz C et al.. 2010. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23.. Annu Rev Med 61:91-104 PMID: 20059333
- 5. Magen D. 2017. [GENETIC DISORDERS OF RENAL PHOSPHATE HANDLING].. Harefuah 156(10):654-658 PMID: 29072386
- 6. Lee HW et al.. 2022. Acid-base effects of combined renal deletion of NBCe1-A and NBCe1-B.. Am J Physiol Renal Physiol 322(2):F208-F224 PMID: 35001662
- 7. Jüppner H et al.. 2010. FGF-23: More than a regulator of renal phosphate handling?. J Bone Miner Res 25(10):2091-7 PMID: 20593414
- 8. Turner ME et al.. 2023. Vascular calcification maladaptively participates in acute phosphate homeostasis.. Cardiovasc Res 119(4):1077-1091 PMID: 36190819
